# Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

> **NCT01068249** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 42 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Letrozole
- **DRUG:** RAD001 (Everolimus)

## Key facts

- **NCT ID:** NCT01068249
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-04-30
- **Primary completion:** 2022-04
- **Final completion:** 2028-04-30
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068249, "Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01068249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*